

Study characteristics	(n=3800)		P value
	At recruitment	At analysis	
Mean age, year (SD)	61.9 (8.1)	67.2 (8.1)	
Sex, no. (%)			
Male	2215 (58.3)		
Female	1585 (41.7)		
Race, no. (%)			
Chinese	2592 (68.2)		
Malay	799 (21.0)		
Indian	301 (7.9)		
Others	108 (2.8)		

Study characteristics	(n=3800)		P value
	At recruitment	At analysis	
Clinic, no. (%)			
Clinic A	1441 (37.9)		
Clinic B	645 (17.0)		
Clinic C	541 (14.2)		
Clinic D	588 (15.5)		
Clinic E	585 (15.4)		
Smoking status, no. (%)			
Non-smoker	NA	2580 (67.9)	
Ex-smoker	NA	408 (10.7)	
Smoker	NA	407 (10.7)	
Unknown	NA	405 (10.7)	
Presence of chronic diseases, no. (%)			
Hyperlipidaemia	NA	3754 (98.8)	
Hypertension	3513 (92.4)	3701 (97.4)	<0.001 ^a
Diabetes mellitus	3529 (92.9)	3583 (94.3)	<0.001 ^a
Clinical parameters			
Median eGFR, ml/min/1.73 m ² (IQR)	82.7 (29.6)	69.0 (36.0)	<0.001 ^b
Median BMI, kg/m ² (IQR)	NA	26.6 (6.1)	
Median HbA1c, % (IQR)	7.4 (1.5)	7.3 (1.6)	<0.001 ^b
Median SBP, mmHg (IQR)	132 (17)	130 (16)	<0.001 ^b
Median DBP, mmHg (IQR)	73 (12)	70 (12)	<0.001 ^b
Underwent HALT-CKD counselling, no. (%)	NA	3529 (92.9)	
ACEi/ARB usage, no. (%)			<0.001 ^a
Not on medication	286 (7.5)	382 (10.1)	
On medication	2158 (56.8)	1547 (40.7)	
On maximum dose of medication	1356 (35.7)	1871 (49.2)	
SGLT2i usage, no. (%)	NA	1506 (39.6)	
Progression to CKD G3B–G5, no. (%)		480 (12.6)	
Patients with worsening G category, ^c no. (%)		1558 (41.0)	
Patients with worsening A category, ^d no. (%)		641 (16.9)	

^a McNemar test

^b Wilcoxon signed-rank test

^c Worsening CKD G category (e.g. G1–G2 or G3A–G3B)

^d Worsening CKD A category (e.g. A1–A2 or A2–A3)

ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; CKD: chronic kidney disease; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; HALT-CKD: Holistic Approach to Lowering and Tracking Chronic Kidney Disease; Hb1Ac: haemoglobin 1Ac; IQR: interquartile range; NA: not applicable; SBP: systolic blood pressure; SD: standard deviation; SGLT2i: sodium-glucose cotransporter-2 inhibitor